ℹ️ Compiled from public regulatory records · Last regulator revision: May 8, 2026🚩 Report this page

Siponimod

Sphingosine-1-Phosphate (S1p) Receptor Modulators

Sold as MAYZENT

CA Health CanadaEU EMA

Drug class: Sphingosine-1-Phosphate (S1p) Receptor Modulators
Availability: See label
Routes: Oral
Markets covered: 2
Products on record: 4

L04AESphingosine-1-Phosphate (S1p) Receptor Modulators

Overview

Siponimod is an active pharmaceutical ingredient in the Sphingosine-1-Phosphate (S1p) Receptor Modulators group (L04AE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
CA Canada	Health Canada	3	July 25, 2025
EU European Union	EMA	1	May 8, 2026

CACanada· Health Canada

3 products

Side effects & warnings

CAOfficial regulatory label· Warnings and precautions· revised July 25, 2025[1]

, General). 3 Pharmacokinetics, Special Populations and Conditions – Genetic Polymorphism). , immunodeficiency syndrome). , hepatitis, tuberculosis), until resolution of the infection (see 7 WARNINGS AND PRECAUTIONS, Immune). • Patients with known active malignancies, except localized basal cell carcinoma of the skin (see 7 WARNINGS AND PRECAUTIONS, Neoplasm).
• Patients who in the last 6 months had myocardial infarction (MI), unstable angina pectoris, stroke/transient ischemic attack (TIA), decompensated heart failure (requiring inpatient MAYZENT® (siponimod) Page 5 of 56 treatment), or New York Heart Association Class III/IV heart failure (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).
• Patients with second degree Mobitz type II atrioventricular (AV) block, third degree AV block, or sick sinus syndrome, if they do not have a pacemaker (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular). • Women (including female adolescents) who are pregnant or of childbearing potential not using effective contraception.

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised May 8, 2026[2]

1).

How to take

EUOfficial regulatory label· revised May 8, 2026

Drug interactions

Known interactions involving Siponimod. Select one for details. This list is informational and not a complete interaction checker.

Abarelix Abatacept Abemaciclib Abiraterone Acalabrutinib Acebutolol Adalimumab Adenosine Aflibercept Aldesleukin Alectinib Alefacept Alemtuzumab Alfuzosin Altretamine Ambenonium Amiodarone Amisulpride Amitriptyline Amlodipine Amoxapine Amprenavir Anagrelide Anakinra Antilymphocyte Immunoglobulin Apalutamide Apomorphine Aprepitant Arsenic Trioxide Asenapine Asparaginase Astemizole Atazanavir Atenolol Atezolizumab Atomoxetine Avapritinib Axicabtagene Ciloleucel Azacitidine Azathioprine Azithromycin Baricitinib Basiliximab Bedaquiline Belantamab Mafodotin Belatacept Belimumab Belinostat Bendamustine Bepridil Berotralstat Betamethasone Betaxolol Bexarotene Bicalutamide Bisoprolol Bleomycin Blinatumomab Boceprevir Bortezomib Bosentan Bosutinib Brentuximab Vedotin Brexucabtagene Autoleucel Brigatinib Brodalumab Budesonide Buprenorphine Busulfan Cabazitaxel Cabozantinib Canakinumab Capecitabine Carbamazepine Carboplatin Carfilzomib Carmustine Carteolol Carvedilol Cenobamate Ceritinib Certolizumab Pegol Cevimeline Chlorambucil Chloramphenicol Chloroquine Chlorpromazine Cilostazol Cimetidine Ciprofloxacin Cisapride Cisplatin Citalopram Cladribine Clarithromycin Clevidipine Clofarabine Clofazimine Clomipramine Clozapine Cobicistat Cobimetinib Conivaptan Copanlisib Corticotropin Cosyntropin Crizotinib Cyclophosphamide Cyclosporine Cytarabine Dabrafenib Dacarbazine Dactinomycin Dalfopristin Daratumumab Darunavir Dasatinib Daunorubicin Decitabine Deflazacort Degarelix Delavirdine Demecarium Denileukin Diftitox Desipramine Deutetrabenazine Dexamethasone Digitoxin Digoxin Diltiazem Dimethyl Fumarate Dinutuximab Diroximel Fumarate Disopyramide Docetaxel Dofetilide Dolasetron Donepezil Doxepin Doxorubicin Dronedarone Droperidol Dupilumab Durvalumab Duvelisib Edrophonium Efalizumab Efavirenz Elotuzumab Encorafenib Entrectinib Enzalutamide Epirubicin Eribulin Erythromycin Escitalopram Eslicarbazepine Esmolol Etanercept Etoposide Etravirine Everolimus Ezogabine Famotidine Fedratinib Felodipine Fenofibrate Flecainide Floxuridine Fluconazole Fludarabine Fludrocortisone Fluorouracil Fluoxetine Fluphenazine Flutamide Fluvoxamine Fosamprenavir Fosaprepitant Foscarnet Fosphenytoin Fostemsavir Galantamine Gatifloxacin Gemcitabine Gemfibrozil Gemifloxacin Gemtuzumab Ozogamicin Gilteritinib Glasdegib Golimumab Goserelin Granisetron Grepafloxacin Guselkumab Halofantrine Haloperidol Halothane Histrelin Hydrocortisone Hydroxychloroquine Hydroxyurea Hydroxyzine Ibritumomab Tiuxetan Ibrutinib Ibutilide Idarubicin Idelalisib Ifosfamide Iloperidone Imatinib Imipramine Indinavir Inebilizumab Infliximab Inotuzumab Ozogamicin Interferon Alfa-2b Interferon Alfa-N1 Interferon Alfacon-1 Interferon Gamma-1b Irinotecan Isatuximab Isavuconazonium Isoflurophate Isradipine Itraconazole Ivabradine Ivosidenib Ixabepilone Ixazomib Ixekizumab Ketoconazole Labetalol Lacosamide Lapatinib Lasmiditan Lefamulin Leflunomide Lenalidomide Lenvatinib

Showing 240 of 519. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]Health Canada (DPD) · 02496429 · revised July 25, 2025
[2]European Medicines Agency · EMEA/H/C/004712 · revised May 8, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.